This Phase IIIb, open-label study assessed the efficacy and safety of pasireotide in patients with acromegaly who had uncontrolled GH and IGF-I levels for ≥3 months despite medical treatment with first-generation SSAs. The gene discussed is IGF1; the disease is acromegaly.